Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01170897 · ClinicalTrials.gov registry record · Phase 1
Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Halozyme Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 27
- Enrollment target
NCT01170897 is a Phase 1 study that has completed, run by Halozyme Therapeutics. The registered enrollment target is 27 participants.
The verdict
NCT01170897, a Phase 1 study, has completed, sponsored by Halozyme Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 27 participants
- Enrollment target
Study Summary
This is an open-label, multicenter, dose-escalation, safety, tolerability, pharmacokinetic and pharmacodynamic study in patients with advanced solid tumors.
Interventions
- DRUG PEGPH20
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 27 participants |
| Start Date | 2010-07 |
| Est. Completion | 2014-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01170897
The ClinicalTrials.gov registry entry for NCT01170897 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 27 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Halozyme Therapeutics, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PEGPH20 is the first listed.
NCT01170897 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01170897 about?
NCT01170897 is a clinical study titled "Study of PEGPH20 With Initial Dexamethasone Premedication Given Intravenously to Patients With Advanced Solid Tumors". This is an open-label, multicenter, dose-escalation, safety, tolerability, pharmacokinetic and pharmacodynamic study in patients with advanced solid tumors.
What is the current status of trial NCT01170897?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 27 participants. The study started on 2010-07. Estimated completion is 2014-01.
What interventions are being tested in trial NCT01170897?
The interventions under investigation include: PEGPH20 (DRUG).
Who is sponsoring clinical trial NCT01170897?
This trial is sponsored by Halozyme Therapeutics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.